Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Stéphanie Guidez

10PUBLICATIONS

66CO-AUTHORS

Haematological tumoursMolecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Reproduction

Featured researcher

Get your video featured.

Publish with JoVE

Featured researcher

Get your video featured.

Publish with JoVE

Publications (10)

Sort by Publication Date:

|Mar 31, 2026

Lenalidomide plus rituximab for previously untreated advanced follicular lymphoma: the 10-year RELEVANCE trial analysis.

Nicolas Gower, Pierre Feugier, Jason R Westin

|Dec 22, 2025

Efficacy and Safety of Capivasertib (AZD5363), a Potent, Oral Pan-AKT Inhibitor, in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL).

Daniel J Hodson, Geoffrey Shouse, Ho-Jin Shin

|Oct 22, 2025

Late failure of aggressive B-cell lymphoma after CAR T-cell therapy: a LYSA study from the DESCAR-T registry.

Federico Erbella, Emmanuel Bachy, Guillaume Cartron

|Sep 30, 2025

Outcome of patients with mantle cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T study by LYSA Group.

Marion Aymard, Morgane Cheminant, Roch Houot

|Aug 04, 2025

Brentuximab vedotin addition to gemcitabine in relapsed or refractory peripheral T-cell lymphoma: a LYSA phase 2 study.

Olivier Tournilhac, Kamal Bouabdallah, Solène Lecolant

|Apr 26, 2025

Atezolizumab, obinutuzumab and venetoclax for the treatment of patients with relapsed/refractory B non-Hodgkin lymphoma: Final analysis of a phase II trial from the LYSA group.

Charles Herbaux, Emmanuel Bachy, Reda Bouabdallah

Pageof 2

Frequent Collaborators

7 joint publications

Franck Morschhauser

5 joint publications

Guillaume Cartron

5 joint publications

Sylvain Carras

5 joint publications

Roch Houot

5 joint publications

Steven Le Gouill

4 joint publications

Emmanuel Bachy

4 joint publications

Charles Herbaux

3 joint publications

Sylvain Choquet

3 joint publications

Gabriel Brisou

3 joint publications

Michael Loschi

Frequent Collaborators

7 joint publications

Franck Morschhauser

5 joint publications

Guillaume Cartron

5 joint publications

Sylvain Carras

5 joint publications

Roch Houot

Top Related Videos

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Published on : May 02, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on : Feb 21, 2025

See more related videos

Top Related Videos

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Laparoscopic Anatomical Resection of the Right Anterior Lobe Based on the Laennec Capsule Technique

Published on : May 02, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [<sup>18</sup>F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on : Feb 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on : Feb 21, 2025

See more related videos